title: Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.
abstract: Since it was first recognized in 2004 that human parechoviruses (HPeV) are a significant cause of central nervous system and neonatal sepsis, their clinical importance, primarily in children, has started to emerge. Intravenous immunoglobulin treatment is the only treatment available in such life-threatening cases and has given moderate success. Direct inhibition of parechovirus infection using monoclonal antibodies is a potential treatment. We have developed two neutralizing monoclonal antibodies against HPeV1 and HPeV2, namely, AM18 and AM28, which also cross-neutralize other viruses. Here, we present the mapping of their epitopes using peptide scanning, surface plasmon resonance, fluorescence-based thermal shift assays, electron cryomicroscopy, and image reconstruction. We determined by peptide scanning and surface plasmon resonance that AM18 recognizes a linear epitope motif including the arginine-glycine-aspartic acid on the C terminus of capsid protein VP1. This epitope is normally used by the virus to attach to host cell surface integrins during entry and is found in 3 other viruses that AM18 neutralizes. Therefore, AM18 is likely to cause virus neutralization by aggregation and by blocking integrin binding to the capsid. Further, we show by electron cryomicroscopy, three-dimensional reconstruction, and pseudoatomic model fitting that ordered RNA interacts with HPeV1 VP1 and VP3. AM28 recognizes quaternary epitopes on the capsid composed of VP0 and VP3 loops from neighboring pentamers, thereby increasing the RNA accessibility temperature for the virus-AM28 complex compared to the virus alone. Thus, inhibition of RNA uncoating probably contributes to neutralization by AM28.
  
  
  OBJECTIVE
  Human parechoviruses can cause mild infections to severe diseases in young children, such as neonatal sepsis, encephalitis, and cardiomyopathy. Intravenous immunoglobulin treatment is the only treatment available in such life-threatening cases. In order to develop more targeted treatment, we have searched for human monoclonal antibodies that would neutralize human parechoviruses 1 and 2, associated with mild infections such as gastroenteritis and severe infections of the central nervous system, and thus allow safe treatment. In the current study, we show how two such promising antibodies interact with the virus, modeling the atomic interactions between the virus and the antibody to propose how neutralization occurs. Both antibodies can cause aggregation; in addition, one antibody interferes with the virus recognizing its target cell, while the other, recognizing only the whole virus, inhibits the genome uncoating and replication in the cell.
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Shabih
authors.initials: S
authors.lastname: Shakeel
authors.affiliation: Department of Medical Microbiology, Laboratory of Clinical Virology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Westerhuis
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Ari
authors.initials: A
authors.lastname: Ora
authors.affiliation: Department of Medical Microbiology, Laboratory of Clinical Virology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
authors.forename: Gerrit
authors.initials: G
authors.lastname: Koen
authors.affiliation: AIMM Therapeutics, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Arjen Q
authors.initials: AQ
authors.lastname: Bakker
authors.affiliation: AIMM Therapeutics, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Claassen
authors.affiliation: AIMM Therapeutics, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Koen
authors.initials: K
authors.lastname: Wagner
authors.affiliation: AIMM Therapeutics, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Tim
authors.initials: T
authors.lastname: Beaumont
authors.affiliation: Department of Medical Microbiology, Laboratory of Clinical Virology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
authors.forename: Katja C
authors.initials: KC
authors.lastname: Wolthers
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland sarah.butcher@helsinki.fi.
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Butcher
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000737:chemistry* / Q000276:immunology; D000914:Antibodies, Viral / Q000737:chemistry* / Q000276:immunology; D036022:Capsid Proteins / Q000737:chemistry* / Q000276:immunology; D045744:Cell Line, Tumor; D003429:Cross Reactions; D006801:Humans; D008958:Models, Molecular; D030061:Parechovirus / Q000737:chemistry* / Q000276:immunology; D017433:Protein Structure, Secondary; D020349:Surface Plasmon Resonance
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins